PT Darya-Varia Laboratoria Tbk manufactures and trades pharmaceutical products and cosmetics in Indonesia. It operates in four segments: Prescription Drugs, Consumer Health Products, Export and Toll Manufacturing Services, and Services. The company offers prescription products in various areas of cardiology, analgesics, gastro-hepatology, dermamedic, somatic, cough and cold, antibiotic, women healthcare, antiparasit, vitamin and food supplements, anti fungal, plastic surgery, general surgery, burn, trauma wound, aesthetic medicine, somatik, ear healthcare, and central nerve systems. It also provides Consumer Health products comprising Skin Nutrition under the Natur-E brand; Respiratory products under the Decolgen, ALLERIN EXPECTORANT, Decolsin, NEOZEP, STOP COLD, SILEX, and HERBABLEND brand names for nasal congestion, cough, as well as breathing issues caused by allergy; multivitamins under the Enervon-C, Enervon Active, Enervon Gold, and Supertin brands; vitamin C under the Vicee brand; and supplement for kids with Zinc and vitamin C under the Imunped brand; Biogesic for various types of pain; Diatabs, a anti diarrhea product; and New Enzyplex to prevent indigestion. In addition, the company offers toll manufacturing services for soft gelatin capsules, and sterile injections and low volume solid products. It also exports its products. PT Darya-Varia Laboratoria Tbk was founded in 1976 and is headquartered in Jakarta, Indonesia. PT Darya-Varia Laboratoria Tbk is a subsidiary of Blue Sphere Singapore Pte. Ltd.
Indonesian Market Performance
7D7 Days: 0.6%
3M3 Months: 13.0%
1Y1 Year: 5.8%
YTDYear to Date: 7.7%
Over the last 7 days, the market has remained flat, although notably the Consumer Discretionary sector gained 3.6% in that time. More promisingly, the market is up 5.8% over the past year. As for the next few years, earnings are expected to grow by 7.9% per annum. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.